Since SCLC-Y is more sensitive to mTOR inhibitors [65], it is conceivable that there is a significant overlap between YAP1-positive, chemoresistant, highly metastatic cases, and those enriched with mTOR pathway alterations. This evidence concerns the gene MTOR and small cell lung carcinoma.